share_log

We Ran A Stock Scan For Earnings Growth And Insulet (NASDAQ:PODD) Passed With Ease

We Ran A Stock Scan For Earnings Growth And Insulet (NASDAQ:PODD) Passed With Ease

我們進行了一個股票掃描,以尋找盈利增長,銀休特(納斯達克:PODD)輕鬆通過了。
Simply Wall St ·  08/24 09:59

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. Sometimes these stories can cloud the minds of investors, leading them to invest with their emotions rather than on the merit of good company fundamentals. Loss-making companies are always racing against time to reach financial sustainability, so investors in these companies may be taking on more risk than they should.

對於那些投資於能扭轉乾坤的公司的投機者來說,這是一個很大的誘惑,所以即使沒有營收、沒有盈利和記錄表現不佳的公司,也能夠吸引到投資者。有時這些故事會迷惑投資者的頭腦,導致他們在投資時情感用事,而非根據公司業績的優秀基本面進行投資。虧損公司總是在與時間賽跑,以達到財務可持續性,因此投資這些公司的投資者可能承擔了比該承擔的風險更大。

So if this idea of high risk and high reward doesn't suit, you might be more interested in profitable, growing companies, like Insulet (NASDAQ:PODD). Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business.

如果高風險和高回報的想法不適合您,您可能會對像銀休特(NASDAQ:PODD)這樣盈利增長的公司更感興趣。現在這並不是說該公司提供了最好的投資機會,但盈利能力對業務成功至關重要。

How Fast Is Insulet Growing Its Earnings Per Share?

銀休特的每股收益增長有多快?

In business, profits are a key measure of success; and share prices tend to reflect earnings per share (EPS) performance. Which is why EPS growth is looked upon so favourably. It is awe-striking that Insulet's EPS went from US$0.90 to US$5.64 in just one year. While it's difficult to sustain growth at that level, it bodes well for the company's outlook for the future. But the key is discerning whether something profound has changed, or if this is a just a one-off boost.

在業務中,利潤是成功的關鍵衡量標準;股價往往反映了每股收益(EPS)的表現。這就是爲什麼EPS增長備受青睞。令人驚歎的是,銀休特的EPS從0.90美元增長到5.64美元,僅用了一年時間。雖然很難以那個水平維持增長,但這對公司未來的前景是個好兆頭。但關鍵是辨別是否發生了重大改變,或者這只是一次性提升。

One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. The good news is that Insulet is growing revenues, and EBIT margins improved by 7.5 percentage points to 15%, over the last year. Both of which are great metrics to check off for potential growth.

檢查公司增長的一種方法是查看其營業收入和利息和稅前利潤(EBIT)毛利率的變化。好消息是,銀休特正在增長營業收入,EBIT 毛利率在過去一年提高了7.5個百分點,達到15%。這兩者都是潛在增長的重要指標。

You can take a look at the company's revenue and earnings growth trend, in the chart below. Click on the chart to see the exact numbers.

以下圖表展示了該公司營業收入和盈利增長的趨勢。單擊圖表可以查看準確數字。

1724507987913
NasdaqGS:PODD Earnings and Revenue History August 24th 2024
納斯達克GS:PODD盈利和營業收入歷史數據 2024年8月24日

The trick, as an investor, is to find companies that are going to perform well in the future, not just in the past. While crystal balls don't exist, you can check our visualization of consensus analyst forecasts for Insulet's future EPS 100% free.

作爲投資者的訣竅是找到未來表現良好的公司,而不只是過去。雖然沒有水晶球,但您可以查看我們爲銀休特未來EPS的共識分析師預測的可視化,在這裏完全免費。

Are Insulet Insiders Aligned With All Shareholders?

銀休特內部人與所有股東保持一致嗎?

We would not expect to see insiders owning a large percentage of a US$13b company like Insulet. But thanks to their investment in the company, it's pleasing to see that there are still incentives to align their actions with the shareholders. Holding US$56m worth of stock in the company is no laughing matter and insiders will be committed in delivering the best outcomes for shareholders. This should keep them focused on creating long term value for shareholders.

我們不會指望看到內部人擁有像銀休特這樣一家市值130億美元的公司的大比例股權。但由於他們對公司的投資,令人高興的是仍然有激勵來使他們的行動與股東保持一致。持有價值5600萬美元的公司股票絕非鬧着玩,內部人將致力於爲股東創造最佳業績。這應該使他們專注於爲股東創造長期價值。

Is Insulet Worth Keeping An Eye On?

銀休特是否值得關注?

Insulet's earnings have taken off in quite an impressive fashion. That sort of growth is nothing short of eye-catching, and the large investment held by insiders should certainly brighten the view of the company. The hope is, of course, that the strong growth marks a fundamental improvement in the business economics. So based on this quick analysis, we do think it's worth considering Insulet for a spot on your watchlist. We should say that we've discovered 2 warning signs for Insulet that you should be aware of before investing here.

銀休特的收益增長相當驚人。這種增長是非常引人注目的,內部人持有的大量投資肯定會改善人們對公司的看法。當然,希望這種強勁增長標誌着業務經濟的基本改善。因此,根據這個簡要分析,我們認爲值得考慮將銀休特納入您的自選列表。我們必須說,在此之前,在這裏投資之前,我們發現了2個有警示意義的跡象。

There's always the possibility of doing well buying stocks that are not growing earnings and do not have insiders buying shares. But for those who consider these important metrics, we encourage you to check out companies that do have those features. You can access a tailored list of companies which have demonstrated growth backed by significant insider holdings.

總是有可能買入未增長收益並且內部人員不買入股票的股票表現良好。但是對於那些認爲這些重要指數的人,我們鼓勵您查看具有這些功能的公司。您可以訪問定製列表,其中列出了已經展示出增長並得到內幕人員認可的公司。

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

請注意,本文討論的內部交易是指在相關司法管轄區中報告的交易。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論